IGM Biosciences, Inc. announced that the FDA has cleared two Investigational New Drug applications for imvotamab, an IgM-based CD20 X CD3 bispecific antibody T cell engager, enabling the initiation of Phase Ib studies in both severe systemic lupus erythematosus and severe rheumatoid arthritis.
[IGM Biosciences, Inc.]
